We have to CHANGE the question from WHEN to WHY? | ACAD Message Board Posts


ACADIA Pharmaceuticals Inc.

  ACAD website

ACAD   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  18363 of 18489  at  5/7/2021 4:12:05 PM  by

SuperM


 In response to msg 18362 by  cm4cmc
view thread

Re: We have to CHANGE the question from WHEN to WHY?

Dr.Erin Foff at the CTAD Investor Event (Transcript)

"When we look at the double-blind relapse rates, its again a bit hard to interpret these results given the small numbers and we really were not powered to look at this in any meaningful statistical way. So, the best we can do is just describe it. So, aside from frontotemporal dementia where we had only a single patient relapse and that patient happened to be on pimavanserin.

The take-home here is that the relapsed rates on pimavanserin were a little narrow and low overall in the individual groups ranging from 0 in the DLB population to about 16.7% in the vascular dementia patients, and the range in the group receiving placebo was broader and higher again ranging from 16.7% to about 67%, not taking that FTD group into consideration. The actual relapse rates themselves are shown below."

I got that from Seeking Alpha, I would suggest everyone carefully read the transcript


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 0
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


Financial Market Data provided by
.
Loading...